OBJECTIVE： To observe clinical efficacy and ADR of placenta polypeptide for advanced aged chemotherapy patients with non-small cell lung cancer （NSCLC）. METHODS： 110 advanced age chemotherapy patients with NSCLC  were randomly divided into observation group and control group， with 55 cases in each group. Control group was given chemotherapy regimen of pemetrexed+cisplatin， 3 weeks as a chemotherapy course， for 4 courses； observation group was additionally given Placenta polypeptide injection 8 ml+0.9％ Sodium chloride solution 200 ml， ivgtt， bid， 10 days as a chemotherapy course， on the basis of control group. Clinical efficacy was observed in 2 groups， T lymphocyte subsets and NK cell activity were also observed before and after treatment. KPS， WBC， Hb， PLT and fatigue symptom score were compared before and after treatment， and toxic reaction was evaluated. RESULTS： Total effective rate of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. After treatment， T lymphocyte subsets CD3+， CD4+ and CD4+/CD8+ and NK cell activity of observation group were significantly higher than those of control group， with statistical significance （P＜0.05）； while KPS of observation group was significantly higher than that of control group after treatment， with statistical significance （P＜0.05）. Observation group of patients with OS， PFS was significantly longer than that of control group， the difference was statistically significant （P＜0.05）.After treatment， WBC， Hb and PLT count of observation group were significantly higher than those of control group， symptom scores were significantly lower than those in the control group with statistical significance （P＜0.05）. CONCLUSIONS： The placental peptide can significantly improve clinical efficacy， immune function and reduce toxic reaction in advanced age chemotherapy patients with NSCLC.